Marius Pharmaceuticals Announces Issuance of Two Key Patents Protecting its Proprietary Oral Testosterone Therapy
May 21, 2020 06:30 ET
|
Shah Capital
RALEIGH, N.C., May 21, 2020 (GLOBE NEWSWIRE) -- Marius Pharmaceuticals announced today that the United States Patent and Trademark Office (USPTO) has issued two key patents related to its lead...
CLARUS THERAPEUTICS ANNOUNCES FINANCING TO SUPPORT THE COMMERCIAL LAUNCH AND AVAILABILITY OF JATENZO® (TESTOSTERONE UNDECANOATE) CAPSULES, CIII FOR THE TREATMENT OF HYPOGONADISM
March 16, 2020 08:00 ET
|
Clarus Therapeutics, Inc.
Financing to speed commercialization of the only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., March 16, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics,...
Clarus Therapeutics Announces Commercial Launch and Availability of JATENZO® (testosterone undecanoate) capsules, CIII for the Treatment of Hypogonadism
February 10, 2020 08:00 ET
|
Clarus Therapeutics, Inc.
First and only FDA-approved oral treatment of its kind for testosterone deficiency1,2 NORTHBROOK, Ill., Feb. 10, 2020 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced that JATENZO®...
Clarus Therapeutics Expands Executive Team in Preparation for Landmark Launch of JATENZO® (testosterone undecanoate) Capsules CIII
December 11, 2019 14:04 ET
|
Clarus Therapeutics, Inc.
NORTHBROOK, Ill., Dec. 11, 2019 (GLOBE NEWSWIRE) -- Clarus Therapeutics, Inc. today announced the appointment of five senior leaders, each of whom bring valuable industry and category experience to...
IASO BioMed Announces Addition of Four Members to Its Scientific Advisory Board
November 13, 2018 09:00 ET
|
IASO BioMed, Inc.
Company developing a Next Generation Treatment for Low Testosterone CENTENNIAL, Colo., Nov. 13, 2018 (GLOBE NEWSWIRE) -- IASO BioMed, Inc. (“IASO” or the “Company”), an innovative biotechnology...
Clarus Therapeutics Completes Patient Enrollment in Phase 3 Study of its Proprietary Oral Testosterone Replacement Therapy
May 01, 2012 08:22 ET
|
Clarus Therapeutics Holdings, Inc.
NORTHBROOK, Ill, May 1, 2012 (GLOBE NEWSWIRE) -- Clarus Therapeutics,
Inc., today announced that patient enrollment has been
completed in the Company's pivotal Phase 3 clinical trial of...
![American Heart Association Logo](/news-release/logo/213500/0/213500.jpg?lastModified=12%2F09%2F2016%2022%3A55%3A27&size=2)
Testosterone Supplements May Help Heart Failure Patients
April 17, 2012 16:00 ET
|
American Heart Association
Study Highlights:
Testosterone supplements helped stable heart failure patients with moderate to severe disease breathe better and exercise more, according to a review of four previous...